DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease

The diagnosis of Parkinsonian disorders is currently based on clinical criteria, which have limited sensitivity until most dopaminergic neurons are lost. Here we show that cerebrospinal fluid levels of DOPA decarboxylase (DDC) (also known as aromatic l-amino acid decarboxylase) can accurately identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Joana B., Kumar, Atul, Hall, Sara, Palmqvist, Sebastian, Stomrud, Erik, Bali, Divya, Parchi, Piero, Mattsson-Carlgren, Niklas, Janelidze, Shorena, Hansson, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570139/
https://www.ncbi.nlm.nih.gov/pubmed/37723208
http://dx.doi.org/10.1038/s43587-023-00478-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570139/
https://www.ncbi.nlm.nih.gov/pubmed/37723208
http://dx.doi.org/10.1038/s43587-023-00478-y

Ejemplares similares